Arvinas (ARVN) Total Non-Current Liabilities (2017 - 2018)
Arvinas (ARVN) recorded quarterly Total Non-Current Liabilities of $62.5 million in Q4 2018, down 6.14% quarter-over-quarter from $66.6 million in Q4 2017, and down 6.14% on a YoY basis from $66.6 million in Q4 2017.
Arvinas (ARVN) Total Non-Current Liabilities (2017 - 2018) Analysis & Trends
Arvinas' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $62.5 million for Q4 2018.
- In Q4 2018, Total Non-Current Liabilities fell 6.14% year-over-year to $62.5 million; the TTM figure through Dec 2018 stood at $62.5 million (down 6.14% YoY), while the FY2018 annual figure was $62.5 million, down 6.14% from the prior year.
- Total Non-Current Liabilities was $62.5 million for Q4 2018 at Arvinas, down from $66.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $66.6 million in Q4 2017 to a low of $62.5 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 62.46 Mn |
| Dec 31, 2017 | 66.55 Mn |